Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Venetoclax and azacitidine for AML ineligible for standard induction

Raúl Córdoba • 22 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia Azacitidine Cytarabine Venetoclax
VIALE-A

Raul Cordoba, MD, PhD, of University Hospital Fundación Jiménez Díaz, Madrid, Spain, explores the use of venetoclax and azacitidine in older adults with acute myeloid leukemia (AML) unfit for intensive chemotherapy, as evaluated in the VIALE-A study (NCT02993523) presented at EHA 2020. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Raúl Córdoba

2:03
Comprehensive geriatric assessments can aid in selecting treatment for elderly patients with CLL
Raúl Córdoba • 7 Oct 2023
2:08
The differences in outcomes and treatment in CLL patients with mutated and unmutated IGHV
Raúl Córdoba • 7 Oct 2023
2:12
Real-world safety and efficacy of first- and second-generation BTK inhibitors in CLL
Raúl Córdoba • 7 Oct 2023
2:20
Clinical relevance of geriatric assessment
Raúl Córdoba • 22 Jun 2020

Related Videos

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals